Giant cell myocarditis


 * Associate Editor:

Synonyms and Keywords: GCM, Idiopathic Giant cell myocarditis, IGCM

Overview
Giant cell myocarditis is a rare but often fatal inflammatory process involving the myocardium. Other than cardiac transplantation, there is no known effective treatment for giant cell mycoarditis.

Pathophysiology
Data from a Lewis Rat model and from observational human studies suggest that giant cell myocarditis is mediated by T lymphocytes. The disease may therefore respond to treatment aimed at attenuating T cell function.

Numerous autoimmune disorders have been associated with giant-cell myocarditis in case reports, but the true magnitude of the association and causality of any association (if any) is not clear.

Gross Pathological Findings
Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology

Microscopic Pathological Findings
Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology

Epidemiology and Demographics
Giant cell myocarditis often affects young otherwise healthy individuals.

Complications
Giant cell myocarditis is generally characterized by progressive congestive heart failure, and is frequently associated with refractory ventricular arrhythmias. The majority of patients die secondary to congestive heart failure, although some have survived for long periods, often after immunosuppressive treatment.

Prognosis
The rate of death or heart transplantation is approximately 70% at one year. Survival following cardiac transplantation is approximately 71% at five years despite a 25% rate of giant cell infiltration in the donor heart.

Endomyocardial Biopsy
The Giant Cell Myocarditis Registry is a clinical and pathologic database from 63 cases of giant cell myocarditis gathered from 36 medical centers. Using pathologic examination at transplantation or autopsy as the gold standard, the sensitivity of endomyocardial biopsy in detecting GCM was 80% in the GCM registry. .

Electrocardiogram
Heart block is frequently observed in giant cell myocarditis.

Immunosuppressive therapy
Immunosuppressive therapy including muromonab-CD3, cyclosporine and/or azathioprine, and steroids has been used to treat giant cell myocarditis. Giant Cell Myocarditis Registry subjects who received cyclosporine and/or azathioprine, with steroids and sometimes muromonab-CD3 had prolonged transplant-free survival: 12.6 months vs 3.0 months for those patients treated with no immunosuppression. . While these data are encouraging, it should be noted that they are drawn from a modest registry experience and randomized placebo-controlled trials are lacking.

Cardiac Transplantation
Giant cell myocarditis may recur after cardiac transplantation but may respond to augmented immunosuppression.